Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Patient Selection
100%
Nintedanib
100%
Platelet-derived Growth Factor Receptor (PDGFR)
50%
Confidence Interval
33%
TP53 mutation
33%
Fibroblast Growth Factor Receptor 1 (FGFR1)
33%
Partial Response
33%
Vascular Endothelial Growth Factor Receptor (VEGFR)
33%
Stable Disease
33%
Objective Response Rate
33%
Response Rate
16%
Disease Progression
16%
Progression-free Survival
16%
Adverse Events
16%
Twice Daily
16%
Diarrhea
16%
Nausea
16%
Median Overall Survival
16%
Median Progression-free Survival
16%
Myocardial Infarction
16%
Previously Treated
16%
Metastatic Non-small Cell Lung Cancer
16%
Adenocarcinoma
16%
Bleeding Risk
16%
Thrombosis Risk
16%
Weight Loss
16%
Specific mutation
16%
Systemic Therapy
16%
Exclusion Criteria
16%
Platinum-based Chemotherapy
16%
Clinical Benefit
16%
Blood Vessels
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
16%
Heavily Pretreated
16%
Disease Control Rate
16%
Tumor Protein p53 (TP53)
16%
Anorexia
16%
Necrotic Tumor
16%
Small Molecule Tyrosine Kinase Inhibitors
16%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Nintedanib
100%
Platelet Derived Growth Factor Receptor
66%
Diseases
50%
Progression Free Survival
33%
Immunotherapy
33%
Neoplasm
16%
Nausea
16%
Adverse Event
16%
Diarrhea
16%
Arm
16%
Overall Survival
16%
Disease Exacerbation
16%
Myocardial Infarction
16%
Adenocarcinoma
16%
Thrombosis
16%
Thromboembolism
16%
Systemic Therapy
16%
Vasculotropin Receptor
16%
Vascular Bundle
16%
Fibroblast Growth Factor Receptor
16%
Anorexia
16%
Response Evaluation Criteria in Solid Tumors
16%
Tyrosine-Kinase Inhibitor
16%
Fibroblast Growth Factor Receptor 1
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Nintedanib
100%
Platelet Derived Growth Factor Receptor
66%
Diseases
50%
Progression Free Survival
33%
Immunotherapy
33%
Neoplasm
16%
Diarrhea
16%
Nausea
16%
Adverse Event
16%
Overall Survival
16%
Chemotherapy
16%
Heart Infarction
16%
Adenocarcinoma
16%
Solid Malignant Neoplasm
16%
Disease Exacerbation
16%
Fibroblast Growth Factor Receptor
16%
Thromboembolism
16%
Vasculotropin Receptor
16%
Thrombosis
16%
Anorexia
16%
Protein Tyrosine Kinase Inhibitor
16%
Fibroblast Growth Factor Receptor 1
16%